SETD2 and hematologic disorder: SETD2 is encoded by a tumor suppressor whose loss of function (via biallelic inactivating mutations, or monoallelic deletions or copy neutral loss of heterozygosity and mutation of the remaining allele) has been observed in a variety of solid tumors and, more recently, in hematologic malignancies of both myeloid and lymphoid origin [15].